Business research

Biocon Q4 review – Strong growth in generics business and research services: Nirmal Bang

BQ Blue’s special research section brings together in-depth and quality research reports on stocks and the economy from India’s leading brokers, asset managers and research agencies. These reports offer BloombergQuint subscribers the opportunity to broaden their understanding of companies, sectors and the economy.

Biocon Ltd. recorded strong revenue growth (11% QoQ), driven by generics and research services activities, but the biosimilar activity was stable QoQ.

The surge in US insulin Glargine prescription volume was potentially offset by lower revenue in other geographies/lower US supply revenue

We believe that Biocon’s increase in market share to over 50% in everolimus was the key driver of growth in the generics business, which increased 18% quarter-on-quarter.

As more generic players enter Everolimus, the generics business base may correct from current levels.

Viatris, Teva, and Par Pharma are other companies that have an approval for Everolimus 10mg, but have yet to launch.

We estimate the contribution of Everolimus to the generics business at approximately 15%.

Click on the attachment to read the full report:


This report is written by an external party. BloombergQuint does not guarantee the accuracy of its content and is in no way responsible for it. The content of this section does not constitute investment advice. For this, you should always consult an expert based on your individual needs. The views expressed in the report are those of the authoring entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify or distribute content without permission from the original owner.